Clinical Trials
4
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)
Phase 1
Recruiting
- Conditions
- Chemotherapy-induced Thrombocytopenia (CIT)
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT05426369
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04123886
- Locations
- 🇨🇳
West China Hospitial, Sichuan University, Chengdu, Sichuan, China
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04051112
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04047771
- Locations
- 🇨🇳
Beijing Shijitan Hospital Capital Medical University, Beijing, Beijing, China
News
No news found